August 5th, 2014
bioCSL Inc. to supply U.S. Market with 16.5 Million Doses
Historical reliability, coupled with dedicated commercial and production efforts, drive strong customer prebook order demand
Early season deliveries will support U.S. providers’ 2014-15 vaccination needs
bioCSL Inc. announced today it has commenced shipping its seasonal influenza vaccine AFLURIA(Influenza Vaccine) for the 2014-2015 flu season. U.S. providers who ordered AFLURIA may be able to begin vaccinating as early as this month.
Reflecting bioCSL’s longstanding commitment to public health and improving seasonal influenza vaccination rates, bioCSL Inc. will deliver about 16.5 million doses of the 2014-2015 formulation of AFLURIA, with approximately 75 percent of doses in thimerosal-free pre-filled syringes.
“Our historical operational focus on early and consistent delivery has resulted in a strong customer prebook order demand for the coming season,” said Dr. Marie Mazur, President of bioCSL Inc. “We are committed to continuing to serve the needs of providers in the United States, and want to ensure that they are prepared to help prevent influenza in their communities.”
The impact of the 2013-14 influenza season was especially detrimental to the health of 18-64 year old adults. Approximately 60 percent of the reported influenza-associated hospitalizations were among people between the ages of 18 and 64. While the Centers for Disease Control and Prevention (CDC) recommends that everyone between the ages of 18-64 be vaccinated against the flu, this age group lags behind the national average. Based on early season estimates of people between the ages of 18 and 64, only 44 percent who were at high risk and only 30 percent who were not at high risk were vaccinated in the 2013/2014 season.
“With each influenza season comes new challenges,” said Dr. Mazur. “The flu is a significant public health threat. bioCSL Inc. strives to deliver vaccines to providers as early as possible to give them ample time to vaccinate against the flu.”
AFLURIA is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes A and type B present in the vaccine. AFLURIA is approved for use in persons 5 years of age and older.